Latest Osteonecrosis of the jaw Stories
Bernstein Liebhard LLP reports on a study, which found that the FDA approved more new drugs quicker than health regulatory agencies in Europe and Canada. New
New research shows when it comes to bone-cancer-related fractures, pain can be reduced by drug treatment, but no one drug is superior.
Bone cancer-related fractures and pain can be reduced by drug treatment, but no one drug is superior.
Ennis & Ennis P.A.
A new analysis of popular bone-building drugs by the US Food and Drug Administration (FDA) could prompt millions of women to rethink their use of such drugs, even though the agency fell short of issuing specific recommendations.
The Food and Drug Administration (FDA) announced today that physicians should reassess patients with osteoporosis who are being treated with a class of drugs called bisphosphonates after three to five years of therapy to determine whether they should continue treatment.
Continuing a popular but controversial treatment for osteoporosis could reduce spine fracture risk for a particular group of patients, but others could see little to no change if they discontinue it.